top of page



Dr. Helen Pentikis co-founded SAJE Consulting in 2008 and has more than 28 years of experience in the development of new drugs and therapeutics.  She has participated in more than 75 FDA regulatory meetings, representing scientific interests in pharmacology/toxicology, clinical pharmacology, biopharmaceutics, and regulatory strategy.  Dr. Pentikis has authored more than 80 abstracts/publications and has been involved in more than 150 clinical studies in adult and pediatric patients, including Phase 1-3 studies, with a concentration in anti-infectives, women’s health products, CNS, oncology, and oncology supportive care.

Most recently, Dr. Pentikis was the CSO and Co-Founder of Symbiomix Therapeutics, a venture-backed company that was sold to Lupin Pharmaceuticals, Inc., in 2017, after achieving NDA approval for Solosec™. Prior to Symbiomix, Dr. Pentikis served as Head, Clinical Pharmacology at AkaRx Inc., with oversight for all clinical pharmacology activities and management for the company’s lead oncology product. Dr. Pentikis’ work and position on the senior management team was instrumental in the $300M acquisition of AkaRx. Her other experiences include: Founder of SAJE Pharma, Global VP, Pharmacokinetics and Pharmacodynamics at ICON plc,  Senior Research Fellow at Sanofi-Aventis, and FDA Reviewer in the Office of Clinical Pharmacology. 

Dr. Pentikis received a B.S. in Biology from Wake Forest University, a Ph.D. in Pharmacology and Toxicology from the University of Maryland, and completed a Pharmacokinetics Fellowship at the FDA.   She serves as a grant reviewer for the Maryland Innovation Initiative and has served as a board member for Redivivus Therapeutics. 

In addition to her scientific interests, Dr. Pentikis serves the community as an Executive Board Member of the Saint Demetrios Greek Orthodox Church and a mentor for pharmacy students at the University of Notre Dame in Maryland.  She consistently supports The American Hellenic Educational Progressive Association, the Downtown Baltimore Family Alliance, the Hampden Family Center, and the Susan G. Komen Foundation.


Dr. Braun passed away in 2016 of complications related to angiosarcoma.  During her career, Dr. Braun utilized her unique expertise, which spanned more than 25 years, to assist pharma companies with their drug development programs.  Her experiences at the FDA, small pharma, and at consulting companies shaped so many drug development programs, many of which are now FDA approved therapeutics.  Her legacy continues to influence many scientists in the industry to use the highest standards of clinical and regulatory science to bring needed medicines to patients. 

Team: FAQ
bottom of page